Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071866 | 0.86 | ADRB1 (0.50) | ADRB1MEN1KMT2AAKR1C3MAPT | |
| SCHEMBL10063748 | 0.85 | ADRB1 (0.70) | ADRB1MEN1KMT2AAKR1C3MAPT | |
| SCHEMBL3414344 | 0.85 | ADRB1 (0.70) | ADRB1MEN1KMT2AAKR1C3MAPT | |
| SCHEMBL7105773 | 0.85 | ADRB1 (0.70) | ADRB1MEN1KMT2AAKR1C3MAPT | |
| SCHEMBL18118476 | 0.80 | ADRB1 (0.64) | ADRB1MEN1KMT2AAKR1C3MAPT | |
| SCHEMBL327765 | 0.80 | ADRB1 (0.64) | ADRB1MEN1KMT2AAKR1C3MAPT | |
| SCHEMBL28567064 | 0.78 | ADRB1 (0.61) | ADRB1MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL82441 | 0.78 | ADRB1 (0.61) | ADRB1MEN1KMT2AMAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL16446845 | 0.78 | ADRB1 (0.61) | ADRB1MEN1KMT2AAKR1C3MAPT | |
| SCHEMBL81881 | 0.78 | ADRB1 (0.61) | ADRB1MEN1KMT2AMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3218376-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| EP-1415986-B1 | SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BANYU PHARMA CO LTD (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| CN-1777612-A | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | PREDIX PHARMACEUTICALS HOLDING (US) | 2006-05-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | ADRB1 976/4885MEN1 1364/4885KMT2A 165/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | ADRB1 976/4885MEN1 1364/4885KMT2A 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.